001     129236
005     20240228143413.0
024 7 _ |a 10.1002/ajh.24533
|2 doi
024 7 _ |a pmid:27508939
|2 pmid
024 7 _ |a 0361-8609
|2 ISSN
024 7 _ |a 1096-8652
|2 ISSN
024 7 _ |a altmetric:10474116
|2 altmetric
037 _ _ |a DKFZ-2017-05241
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Merz, Maximilian
|b 0
245 _ _ |a Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
260 _ _ |a New York, NY
|c 2016
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1525683878_14692
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Deletion 17p13, del(17p), is associated with poor outcome in myeloma but some patients show long-term survival. With the current study we intended to identify factors impacting outcome of such high risk patients. We analyzed 110 newly diagnosed, symptomatic patients with del(17p) detected by fluorescence in situ hybridization (FISH) in CD138-purified myeloma cells to identify prognostic factors for survival. Age >65 years, ISS III, and elevated LDH negatively impacted survival. Patients with subclonal (10-60% of plasma cells) del(17p) had longer progression-free survival (PFS) than patients with del(17p) in >60% of plasma cells (26 vs. 19 months, P = 0.03). Additional gain of 1q21 was associated with shorter PFS (17 vs. 25 months, P = 0.01). Hyperdiploidy did not ameliorate impact of del(17p), but gain 19q13 predicted longer PFS (30 vs. 18 months, P = 0.01) and overall survival (50 vs. 29 months, P = 0.01). Multivariate analysis in transplant eligible patients (≤65 years) revealed better survival for patients treated with upfront autologous transplantation (hazard ratio, [95% confidence interval]: 0.15 [0.04, 0.58], P = 0.006). Application of maintenance therapy was associated with better survival in transplant-eligible patients (0.30 [0.09, 0.99], P = 0.05). We demonstrate heterogeneous outcome of patients with del(17p) according to baseline characteristics and treatment. 19q13 should be included in routine FISH panel, since gains were associated with better survival. Am. J. Hematol. 91:E473-E477, 2016. © 2016 Wiley Periodicals, Inc.
536 _ _ |a 315 - Imaging and radiooncology (POF3-315)
|0 G:(DE-HGF)POF3-315
|c POF3-315
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 1
|u dkfz
700 1 _ |a Seckinger, Anja
|b 2
700 1 _ |a Hose, Dirk
|b 3
700 1 _ |a Mai, Elias K
|0 0000-0002-6226-1252
|b 4
700 1 _ |a Raab, Marc-Steffen
|0 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3
|b 5
|u dkfz
700 1 _ |a Goldschmidt, Hartmut
|0 P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96
|b 6
|u dkfz
700 1 _ |a Jauch, Anna
|b 7
700 1 _ |a Hillengass, Jens
|0 P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5
|b 8
|e Last author
|u dkfz
773 _ _ |a 10.1002/ajh.24533
|g Vol. 91, no. 11, p. E473 - E477
|0 PERI:(DE-600)1492749-4
|n 11
|p E473 - E477
|t American journal of hematology
|v 91
|y 2016
|x 0361-8609
909 C O |o oai:inrepo02.dkfz.de:129236
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)7ccc574e713526d2a22d7acb9b2248c5
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|2 G:(DE-HGF)POF3-300
|v Imaging and radiooncology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AM J HEMATOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
920 1 _ |0 I:(DE-He78)G170-20160331
|k G170
|l Experimentelle Therapien hämatologischer Neoplasien
|x 1
920 1 _ |0 I:(DE-He78)G330-20160331
|k G330
|l KKE Molekulare Hämatologie/Onkologie
|x 2
920 1 _ |0 I:(DE-He78)V964-20160331
|k V964
|l NCT-KliHD
|x 3
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l Radiologie
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)G170-20160331
980 _ _ |a I:(DE-He78)G330-20160331
980 _ _ |a I:(DE-He78)V964-20160331
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21